The short version
- Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
- What to watchFever or flu-like symptoms after use.
How FOXO4-DRI works
FOXO4-DRI is the only compound in this Vault whose mechanism is to break a protein-protein interaction rather than to occupy a binding site, and that difference explains both why it is elegant and why it has not reached a person.
The problem it was designed against. A senescent cell is not merely an old cell. It has permanently exited the cell cycle, it resists apoptosis, and it secretes a mix of cytokines, proteases and growth factors — the senescence-associated secretory phenotype — that damages the tissue around it.
- Injectable
On the goal map: Cellular senescence & senolytics (Longevity & healthspan)
Research on FOXO4-DRI5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Human clinical evidence
No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
No completed human trial
Correlative data
Very limited community use. Reported experience is unreliable here in a specific way: the claimed effect is invisible without tissue sampling — you cannot feel senescent cell clearance, so self-report has nothing real to anchor to.
How the mechanism reads
A peptide that disrupts the FOXO4–p53 interaction. In senescent cells, FOXO4 sequesters p53 in the nucleus, blocking the apoptosis p53 would otherwise trigger. Break that binding and p53 relocates to the mitochondria and the cell dies.
MechanisticThe 2017 rodent paper reporting restored fur density, renal function and fitness in aged and progeroid mice is one of the more striking results in senolytic biology, and it is also essentially the entire evidence base.
Experimental, animal or cellPeptides do not readily cross cell membranes, let alone reach the nucleus. The published construct used a retro-inverso D-amino-acid design specifically to address that.
Mechanistic
Sources
- Tripathi U, et al. Development of a novel senolytic by precise disruption of FOXO4-p53 complex. EBioMedicine 2021 · PMID 34768086
- Le HH, et al. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine 2021 · PMID 34689087
- Han X, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of Cellular and Molecular Medicine 2022 · PMID 35510614
FOXO4-DRI safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Pregnancy, since p53 pathways guide embryonic development.
- Healing from surgery or a wound, since senescent cells help closure.
- Cancer treatment, where the p53 pathway is under deliberate manipulation.
- Kidney or liver disease, as a stable D-isomer peptide may linger.
- Autoimmune disease.
What’s expected
- No human trial exists; nothing is established.
- In mice it cleared senescent cells and improved fitness.
- A transient inflammatory burst as cells die.
Watch for
- Fever or flu-like symptoms after use.
- Slow wound healing.
- Pain over the liver or flanks.
Labs that tell you it’s working
- hs-CRP: a flare after senescent-cell clearance.
- TNF-Alpha (Tumor Necrosis Factor): a SASP cytokine that should fall if the cells are cleared.
- Complete Blood Count: white cell shifts during the clearance.
- Comprehensive Metabolic Panel: liver and kidney handling of a peptide built from D-amino acids.
D-retro-inverso peptide disrupting FOXO4-p53 binding so senescent cells undergo p53-driven apoptosis; never given to a human in a registered trial. PMID 34768086 PMID 35510614
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
FOXO4-DRI FAQ4 common questions
- Is FOXO4-DRI approved for human use?
- No. FOXO4-DRI is a research compound. No completed randomized human trial has given it yet.
- What is FOXO4-DRI researched for?
- Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
- Which labs show whether it's doing anything?
- hs-CRP; TNF-Alpha; Complete Blood Count; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for FOXO4-DRI: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.




